Key result
T-tubule disruption is a key cause of heart failure, and emerging therapies may specifically target junctophilin-2, BIN1, and mechanotransduction to restore t-tubule structure and function.
Targeting t-tubule regulators like junctophilin-2 and BIN1 offers a potential novel therapeutic approach for heart failure.
T-tubule regulators may identify novel heart failure targets; leaves open therapeutic utility pending clinical validation.
PURPOSE OF REVIEW: Membrane invaginations called t-tubules play an integral role in triggering cardiomyocyte contraction, and their disruption during diseases such as heart failure critically impairs cardiac performance. In this review, we outline the growing understanding of the malleability of t-tubule structure and function, and highlight emerging t-tubule regulators which may be exploited for novel therapies. RECENT FINDINGS: sparks. Recent data have indicated that the dyadic anchoring protein junctophilin-2, and the membrane-bending protein BIN1 are key regulators of dyadic formation and maintenance. While the underlying signals which control expression and localization of these proteins remain unclear, accumulating data support an important role of myocardial workload. Although t-tubule alterations are believed to be a key cause of heart failure, the plasticity of these structures also creates an opportunity for therapy. Promising recent data suggest that such therapies may specifically target junctophilin-2, BIN1, and/or mechanotransduction.
No takes yet. Share an insight, caveat, or question.
Manfra et al. (2017) conducted a review in Heart failure. T-tubule regulators (Junctophilin-2, BIN1, mechanotransduction) was evaluated. T-tubule disruption is a key cause of heart failure, and emerging therapies may specifically target junctophilin-2, BIN1, and mechanotransduction to restore t-tubule structure and function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: